# Michael J. Morris

Source: https://nuclide.cc/people/michael-morris/  
Nuclide record `michael-morris` (Person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.

## Summary

Michael J. Morris is Prostate Cancer Section Head on the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He is a medical oncologist known as principal investigator of the VISION trial, which made lutetium-177 PSMA radioligand therapy a standard prostate cancer treatment, and co-led PSMAfore and PSMA PET studies. His selected papers report lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer and the PSMAfore comparison against a change of androgen receptor pathway inhibitor in taxane-naive patients. He chaired the Alliance genitourinary committee and focuses on radioligand therapy and imaging biomarkers.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Prostate Cancer Section Head, Genitourinary Oncology Service
- Specialisms: Prostate cancer; Radiopharmaceuticals; PSMA theranostics

## Sources

- MSK profile: https://www.mskcc.org/cancer-care/doctors/michael-morris
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://nuclide.cc/targets/psma/)
- drugs: [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://nuclide.cc/institutions/mskcc/)
- trials: [PSMAfore](https://nuclide.cc/trials/psmafore/), [VISION](https://nuclide.cc/trials/vision/)
- key papers: [PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC](https://nuclide.cc/key-papers/paper-psmafore-lancet-2024/), [TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-therap-lancet-2021/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://nuclide.cc/key-papers/paper-vision-nejm-2021/)
- pairings: [Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617](https://nuclide.cc/pairings/docetaxel-then-lu177-psma/)
- roadmaps: [PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha](https://nuclide.cc/roadmaps/psma-theranostics-roadmap/)

---
JSON: https://nuclide.cc/api/v1/entities/michael-morris.json